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Essentials • Polyphosphate is present in microorganisms and human cells such as platelets • Polyphosphate modulates coagulation via interactions with multiple proteins • Polyphosphate modulates inflammation by triggering bradykinin release and inhibiting 
complement • Nucleic acids and polyphosphate co-purify and may be contaminated with silica-based methods 
 
Abstract 
This illustrated review focuses on polyphosphate as a potent modulator of the plasma clotting 
cascade, with possible roles in hemostasis, thrombosis and inflammation. Polyphosphates are highly 
anionic, linear polymers of inorganic phosphates that are widespread throughout biology. Infectious 
microorganisms accumulate polyphosphates with widely varying polymer lengths (from a few 
phosphates to over a thousand phosphates long), while activated human platelets secrete 
polyphosphate with a very narrow size distribution (about 60-100 phosphates long).  Work from our 
lab and others has shown that long-chain polyphosphate is a potent trigger of clotting via the contact 
pathway, while polyphosphate of the size secreted by platelets accelerates factor V activation, blocks 
the anticoagulant activity of tissue factor pathway inhibitor, promotes factor XI activation by 
thrombin, and makes fibrin fibrils thicker and more resistant to fibrinolysis.  Polyphosphate also 
modulates inflammation by triggering bradykinin release, inhibiting the complement system, and 
modulating endothelial function. Polyphosphate and nucleic acids have similar physical properties 
and both will trigger the contact pathway—although polyphosphate is orders of magnitude more 
procoagulant than either DNA or RNA. Important caveats in these studies include observations that 
nucleic acids and polyphosphate may co-purify, and that these preparations can be contaminated with 
highly procoagulant microparticles if silica-based purification methods are employed. Polyphosphate 
has received attention as a possible therapeutic, with some recent studies exploring the use of 
polyphosphate in a variety of formulations to control bleeding. Other studies are investigating 
treatments that block polyphosphate function as novel antithrombotics with the possibility of reduced 
bleeding side effects. 
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